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Vaccinia Virus Binds to the Scavenger Receptor
MARCO on the Surface of Keratinocytes
Daniel T. MacLeod1, Teruaki Nakatsuji1,2, Zhenping Wang1, Anna di Nardo1 and Richard L. Gallo1,2
Patients with altered skin immunity, such as individuals with atopic dermatitis (AD), can have a life-threatening
disruption of the epidermis known as eczema vaccinatum after vaccinia virus (VV) infection of the skin. Here, we
sought to better understand the mechanism(s) by which VV associates with keratinocytes. The class A scavenger
receptor known as MARCO (macrophage receptor with collagenous structure) is expressed on human and
mouse keratinocytes and found to be abundantly expressed in the skin of patients with AD. VV bound directly to
MARCO, and overexpression of MARCO increased susceptibility to VV infection. Furthermore, ligands with
affinity for MARCO, or excess soluble MARCO, competitively inhibited VV infection. These findings indicate that
MARCO promotes VV infection and highlights potential new therapeutic strategies for prevention of VV infection
in the skin.
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INTRODUCTION
Vaccinia virus (VV) is a large DNA virus widely known for its
use as a vaccine against the closely related variola virus, the
causative agent of smallpox (Copeman and Banatvala, 1971;
Fulginiti et al., 2003a). Routine administration of this vaccine
was stopped after smallpox was eradicated; however, VV has
been utilized for vaccination of selected high-risk individuals,
such as some individuals serving in the military (Fulginiti
et al., 2003a), and to study the disease mechanisms of
smallpox. Vaccination is accomplished by inoculation in the
skin by scarification of the epidermis. Inoculation typically
results in a localized VV infection of keratinocytes at the
inoculation site. This usually resolves following local innate
immune defense and subsequent development of protective
humoral and cell-mediated immunity. However, individuals
with altered skin immunity, such as those with AD, are at
increased risk of developing severe reactions to inoculation
with VV, such as the disseminated skin infection eczema
vaccinatum (EV; Copeman and Wallace, 1964; Fulginiti et al.,
2003b). Immunocompromised patients and children are also
at a risk of developing severe infections with VV (Lane and
Millar, 1969; Redfield et al., 1987; Sepkowitz, 2003).
Although these individuals are excluded from vaccination
because of the associated risks, severe infections have also
been known to occur in individuals coming into contact with
others who have been recently inoculated with VV (Lane
et al., 1970; Vora et al., 2008).
Although treatments for VV infection exist, none have been
fully evaluated in a controlled setting (Bray, 2003). A better
understanding of the factors controlling the pathogenesis of
VV in the skin would reduce complications resulting from
inoculation with live VV and may also hint at alternative
strategies for treatment of other viruses that share these patho-
genic mechanisms. Some of the most important cellular factors
that determine the outcome of contact with VV include
receptors that are utilized by the virus to bind to and infect
target cells and, alternatively, innate immune receptors that
act to detect the virus and initiate immune responses.
Although some previous studies have been dedicated to
examining these issues, few have done so using keratino-
cytes, the primary target of VV infection in the skin.
A number of cell surface molecules have been previously
identified to mediate VV adsorption to the cell surface and
promote infection. Some strains of VV bind initially to heparan
sulfate or chondroitin sulfate glycosaminoglycans (GAGs), but
others infect cells in a GAG-independent manner (Bengali
et al., 2009). Five viral proteins have been identified so far for
their involvement in binding to the cell surface. A27 and H3
mediate binding to heparan sulfate, whereas D8 binds to
chondroitin sulfate (Chung et al., 1998; Hsiao et al., 1999; Lin
et al., 2000). GAG-independent binding is also possible with
certain strains and certain cell types and involves interactions
between A26 and laminin on the cell surface or between L1
and an undetermined receptor (Chiu et al., 2007; Foo et al.,
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2009). The mechanisms of membrane fusion are complex,
requiring at least 11 proteins on the surface of VV, and the
specific cellular proteins involved in this process have not
been identified yet (Bengali et al., 2009). Studies focusing
specifically on keratinocytes are required to determine which
surface molecules are most critical for VV infection.
Cell surface and intracellular receptors are key elements of
the innate immune system and are primarily thought to serve a
protective role, as defects in innate immunity appear to be
critical to the pathogenesis of EV (Howell et al., 2004, 2006a,b;
2007; Kim et al., 2007). In addition, numerous pro-
teins expressed by VV function to interfere with host defense
responses (reviewed in Haga and Bowie (2005)). Keratino-
cytes are fully competent innate immune cells, expressing a
number of receptors capable of detecting infection by pathogens
such as VV, and can respond with the production of a number
of antimicrobial mediators (Nizet et al., 2001; Kristian et al.,
2003; Schauber et al., 2007). Cells can detect VV infection
through activation of cell surface and intracellular pattern
recognition receptors such as the Toll-like receptors (TLRs).
Keratinocytes express TLRs 1–6, 9, and 10 (Ko¨llisch et al., 2005;
Lebre et al., 2006). A previous study implicated TLR2/6 in the
detection of VV on the cell surface, and melanoma
differentiation–associated gene-5 and the NOD-like receptor
family, pyrin domain–containing 3 inflammasome in detecting
VV inside the cell (Delaloye et al., 2009). In addition, VV DNA
can stimulate innate immune responses in cells after recognition
by TLR8 (Martinez et al., 2010). Furthermore, Sphingosine-1-
phosphate receptor 2 has recently been shown to recognize
lipids derived from viral membranes and trigger the release of
antimicrobial peptides (Wang et al., 2012). Further experiments
are needed to know which of these innate immune receptors
are most critical for keratinocyte responses to VV infection.
Class A scavenger receptors have important roles in innate
immune defense as they bind to extracellular viral double-
stranded RNA and mediate uptake and presentation of double-
stranded RNA to TLR3 in the endosome (Matsumoto et al.,
2003; Saleh et al., 2006; Limmon et al., 2008; Yew et al.,
2010; DeWitte-Orr et al., 2010; Mukhopadhyay et al., 2011).
TLR3 is hypothesized to enable recognition of a DNA virus
such as VV, as virtually all viruses produce double-stranded
RNA at some point during replication (Jacobs and Langland,
1996), which is then released into the extracellular space after
lysis of infected cells (Majde et al., 1998). Scavenger receptors
have also been shown to bind to a variety of bacterial and viral
products (Krieger et al., 1993; Yew et al., 2010). Therefore, it
would be expected that scavenger receptors would function to
alert keratinocytes of the danger from VV infection and provide
a protective role. However, we previously identified that
keratinocytes express the class A scavenger receptor MARCO
and found that, despite the role of this receptor in the innate
immune system, MARCO is exploited by herpes simplex virus
type 1 (HSV-1) to bind to the surface of keratinocytes and
increase infection (Macleod et al., 2013). In this paper, we
hypothesized that MARCO may also serve to enhance VV
infection of keratinocytes. Our findings suggest that MARCO
can have a significant role in the infection of keratinocytes and
that this interaction could have important implications for EV.
RESULTS
MARCO is abundantly expressed in the skin of patients with AD
Patients with AD are susceptible to severe infections with VV
(Copeman and Wallace, 1964; Howell et al., 2004, 2006a).
We recently found that MARCO is expressed in keratinocytes
and is a key receptor in cutaneous HSV-1 infection (Macleod
et al., 2013). Thus, given the susceptibility of AD patients
to HSV-1 and VV, we decided to investigate whether
the expression of MARCO in AD could have a role in the
pathogenesis of these viral skin disorders. First, we tested the
expression of MARCO in normal skin compared with lesional
and non-lesional AD skin. MARCO was expressed evenly
throughout the epidermis of normal skin and non-lesional AD
skin (Figure 1a and b, and Supplementary Figure S1 online).
Strikingly, much greater staining for MARCO was seen in the
epidermis of AD lesional skin. These data confirmed that the
skin of AD patients has abundant MARCO on the surface of
keratinocytes that could potentially interact with VV and have
a role in the susceptibility of individuals with AD to VV
infection. Stimulation of cultured normal human keratinocytes
with cytokines elevated in AD (IL-4 and IL-13) did not
significantly alter MARCO expression (Figure 1c), suggesting
that other factors contributing to AD were responsible for the
increased MARCO expression.
VV binds directly to MARCO
We next sought to identify whether MARCO is capable of
interacting with VV. Keratinocytes express both MARCO and
oxidized low density lipoprotein (lectin-like) receptor 1
scavenger receptors (Macleod et al., 2013). To test for a
direct interaction with VV, we employed a cell-free ELISA
utilizing purified recombinant MARCO. Using this assay, we
found that VV bound specifically to immobilized human and
mouse MARCO protein (Figure 2a and b), demonstrating that
VV binds to MARCO in the absence of any other cell surface
receptor. Importantly, this interaction could be disrupted by
the addition of polyinosinic acid (Poly(I); Figure 2c), a scavenger
receptor ligand known to bind to MARCO (Kodama et al.,
1990; Moriwaki et al., 1998; Chen et al., 2006). VV did not
bind to two additional scavenger receptors, oxidized low
density lipoprotein (lectin-like) receptor 1 (Figure 2d) and
macrophage scavenger receptor 1 (Figure 2e), and an alter-
native enveloped virus, an HIV-1 pseudovirus, did not bind to
MARCO (Figure 2f).
Overexpression of MARCO increases susceptibility to VV
infection
To evaluate the functional significance of the interaction
between VV and MARCO, we next infected wild-type and
MARCO / mice with VV. Interestingly, both wild-type and
MARCO / mice infected with VV had significant and
comparable infiltration of inflammatory cells around the
wound edge and throughout the dermis compared with
uninfected control mice, and lesion sites appeared morpho-
logically similar to each other (Figure 3a). Furthermore, at 6
days post infection, there was no significant difference in the
sizes of wounds in the skin of wild-type and MARCO /
mice (Figure 3b), indicating that MARCO expression is not
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absolutely required for VV infection. However, although
MARCO did not appear to be essential for infection in
whole skin and the absence of MARCO did not alter the
morphology of VV-induced lesions, it remained possible that
the lack of MARCO could be compensated by additional
receptors with similar characteristics. Thus, to further examine
the relationship between the expression of MARCO and the
susceptibility to VV infection, we utilized a keratinocyte cell
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Figure 1. Macrophage receptor with collagenous structure (MARCO)
expression in atopic dermatitis. (a, b) Skin biopsy samples taken from a normal
donor and an atopic dermatitis (AD) donor at non-lesional and lesional sites
were analyzed for Keratin-14 (K14), which is predominantly expressed by basal
keratinocytes, and human MARCO expression and compared with goat IgG
(gIgG) and mouse IgG (mIgG) controls. Scale bars¼50mm. Images in b are one
set of representative images from an experiment with two normal skin donors
and two AD donors (see Supplementary Figure S1 online). (c) Normal human
epidermal keratinocytes (NHEKs) were treated with 50 ng ml 1 IL-4 and/or
IL-13 for 24 hours before RNA isolation and quantitative real-time PCR
for MARCO expression. Error bars indicate SEM, n¼ 3. Differences
between treatment conditions were not significant, as determined by
one-way analysis of variance with Tukey post-tests. DAPI, 4,6-diamidino-2-
phenylindole.
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Figure 2. Vaccinia binds directly to human and mouse macrophage receptor
with collagenous structure (MARCO). Indicated concentrations of vaccinia
virus (VV) were added to plates coated with human MARCO (hMARCO) (a),
mouse MARCO (mMARCO) (b), human oxidized low-density lipoprotein
(lectin-like) receptor 1 (OLR1) (d), and human macrophage scavenger receptor
1 (MSR1) (e). Virus bound to the immobilized protein was quantified by ELISA.
Error bars indicate SEM, n¼ 3, with nonlinear regressions plotted as solid lines.
(c) Plates coated with hMARCO were incubated with 6106 plaque-forming
units (PFU)ml 1 VV in the presence of Poly(I). Bound virus was quantified by
ELISA. Each individual data point is plotted. Data in c were transformed using a
logarithmic x-axis, and the half-maximal inhibitory concentration (IC50) value
and the 95% confidence interval for this value were calculated using
Graphpad Prism. Poly(I) molarity was calculated on the basis of the molecular
weight of each individual nucleotide in the polymer, with average molecules
ranging in length up to 1,000 nucleotides. (f) Indicated amounts of HIV-1
pseudovirus (PsV) were added to plates coated with hMARCO and bound
virus quantified by ELISA. Error bars indicate SEM, n¼2, with nonlinear
regression plotted as a solid line. RLU, relative luminescence units. (a–f) Data
presented are from one representative experiment of two independent
experiments.
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line that stably overexpresses human MARCO protein at levels
approximately 3-fold higher than those of control transfected
cells (Macleod et al., 2013). VV infection of these cells
resulted in significantly more viral plaques (Figure 3b) and
viral DNA (Figure 3c) in the cells that overexpress MARCO
compared with control cells. These experiments demonstrated
that the interaction between MARCO and VV is functionally
significant.
Scavenger receptor antagonists inhibit VV infection of
keratinocytes
A number of studies have previously demonstrated that there
is an overlap in the binding specificities and functions of class
A scavenger receptors (Limmon et al., 2008; DeWitte-Orr
et al., 2010). Thus, as discussed above, the presence of
additional receptors with similar specificity, such as
scavenger receptor class A member 3, collectin subfamily
member 12, or scavenger receptor class F, member 1, which
are expressed by normal human epidermal keratinocytes
(Macleod et al., 2013), may compensate for the absence of
MARCO in MARCO / mice. In this instance, scavenger
receptor ligands that exploit a similar binding specificity
between MARCO and other such receptors would be able to
competitively inhibit binding to VV. Poly(I) and dextran sulfate
are two such ligands that have been extensively characterized
as ligands for class A scavenger receptors (Krieger et al., 1993).
Both of these compounds potently inhibited VV infection of
keratinocytes in a dose-dependent manner (Figure 4a and b).
Poly(I) provided levels of protection comparable to polyinosi-
nic:polycytidylic acid (Poly(I:C)), which also binds to scaven-
ger receptors (Saleh et al., 2006; Limmon et al., 2008;
DeWitte-Orr et al., 2010; Mukhopadhyay et al., 2011).
However, unlike Poly(I:C), Poly(I) is not able to activate
innate immune responses in keratinocytes (Macleod et al.,
2013). In contrast, the similar nucleic acid, polycytidylic acid,
does not bind to scavenger receptors and had no effect on VV
infection (Figure 4a). Thus, these results showed a strong
correlation between scavenger receptor binding and the
capacity to inhibit infection. In light of the absence of an
interaction of VV with oxidized low-density lipoprotein
(lectin-like) receptor 1 and macrophage scavenger receptor 1
(Figure 2d and e), this revealed that, although not all receptors
that bind Poly(I) bind to VV, Poly(I) interferes with the binding
of VV to the cell surface.
Although the similarities in the capacity of Poly(I:C) and
Poly(I) to prevent VV infection indicated that the inhibition
could be attributed to a shared affinity for scavenger receptors
rather than to the ability of Poly(I:C) to activate keratinocyte
innate immune responses, we designed experiments to con-
firm this. We first compared the ability of the treatment of
Poly(I:C) and other TLR ligands to protect against VV infection.
Poly(I:C) significantly protected against VV infection of kera-
tinocytes, but treating with ligands that activate other TLRs (Lai
and Gallo, 2008) did not (Figure 4c). Notably, this inhibitory
effect by Poly(I:C) as measured by viral plaque formation was
dose-dependent and was comparable in both HaCat kerati-
nocytes and normal human epidermal keratinocytes (Figure 4d
and e). This inhibitory effect was also seen when analyzing the
amount of VV early gene mRNA at an early time point after
infection (Figure 4f), indicating that the inhibition was occur-
ring at an early step in the infectious process.
To also test whether protection by Poly(I:C) could be
attributed to activation of innate immune responses, we
treated cells with inhibitors of cellular activation. First, we
used cycloheximide, a potent inhibitor of new protein synth-
esis. Treatment with cycloheximide inhibited the ability of
cells to synthesize new proteins by 97% (data not shown).
However, VV early gene expression is, by definition, not
altered by cycloheximide treatment, thus allowing us to
evaluate the ability of the virus to enter cells and begin viral
RNA synthesis under conditions that block synthesis of new
proteins (Amegadzie et al., 1991). Poly(I:C) inhibited VV
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Figure 3. Overexpression of macrophage receptor with collagenous structure
(MARCO) increases vaccinia virus (VV) infection in keratinocytes. Age-
matched female wild-type (WT) and MARCO / mice were infected with VV
by skin scarification, and 6 days after infection wounds were (a) biopsied for
histology and (b) sizes were quantified. (a) Representative images of the skin of
uninfected WT and MARCO / mice and skin from the edges of the wounds
of mice infected with VV are displayed. Scale bars¼ 50mm. (b) Wound sizes
were quantified with ImageJ, n¼12. (c) HaCat keratinocytes stably
overexpressing MARCO (labeled (MARCO)), or control cells (pcDNA3) were
infected with VV. Plaques were stained and quantified 24 hours after infection,
n¼ 3. (d) HaCat keratinocytes stably overexpressing MARCO (labeled
(MARCO)), or control cells (pcDNA3) were infected with 1,000 plaque-
forming units (PFU) ml1 VV for 24 hours before quantification of viral DNA,
n¼ 3. (b–d) Error bars indicate SEM, and all comparisons were made using
two-tailed Student’s t-tests; NS, not significant, **Po0.01, ***Po0.001. All
data are from representative experiments repeated at least two times.
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infection even under these conditions (Supplementary Figure.
S2a online), indicating that the protective effect of Poly(I:C)
did not involve the synthesis of new antiviral effector proteins.
Next, we tested the effect of treatment with chloroquine, a
potent inhibitor of endosomal acidification. These conditions
prevent the ability of Poly(I:C) to induce IL-6 and IFN-b by
more than 80% (Macleod et al., 2013). Poly(I:C) was able to
protect against VV infection in keratinocytes treated with
chloroquine at levels comparable to the protection seen in
untreated cells (Supplementary Figure S2b online), further
demonstrating that cellular activation by Poly(I:C) was not
required for the protective effect of Poly(I:C). These results
with both cycloheximide and chloroquine also confirmed that
the protective activity of Poly(I:C) occurred at a very early time
point during infection.
To complement these studies, we tested the ability of
soluble recombinant MARCO to inhibit VV infection. Pre-
treatment with recombinant MARCO inhibited VV plaque
formation in normal human epidermal keratinocyte by 54%
(Figure 4g, Po0.001), suggesting that the binding of MARCO
to VV inhibits association of the virus with MARCO and
related scavenger receptors on the cell surface, confirming the
necessity of these molecules for optimal infection of skin cells.
Finally, to test the significance of blocking scavenger
receptors to cutaneous VV infection, we topically applied a
single dose of Poly(I) to the back skin of mice prior to infecting
them with VV. This single dose of Poly(I) moderately reduced
wound size at day 6 post infection, whereas polycytidylic
acid-treated mice had wound sizes comparable to those of
control phosphate-buffered saline-treated mice (Figure 4h).
These results demonstrated that multiple compounds that
share the capacity to restrict access to cell surface scavenger
receptors are capable of inhibiting VV infection in vitro and
in vivo, and further confirmed that the binding interactions
observed between VV and MARCO are functionally relevant.
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Figure 4. Scavenger receptor antagonists prevent vaccinia infection. HaCat
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vaccinia virus (VV) in the presence of the indicated concentrations of (a)
polyinosinic:polycytidylic acid (Poly(I:C)), polyinosinic acid (Poly(I)), and
polycytidylic acid (Poly(C)), or (b) dextran sulfate (Dxs). Plaques were
quantified 24 hours after infection. (a) Poly(I:C)/Poly(I)/Poly(C) molarities were
calculated and normalized on the basis of the molecular weight of each
individual nucleotide in the polymer, with average molecules ranging up to
1,000 nucleotides in length. (a) Two-way analysis of variance with Bonferroni
post-tests was used to compare Poly(I) and Poly(I:C) treatment with Poly(C)
treatment at each concentration; ***Po0.001. (c) HaCat were pretreated with
Toll-like receptor (TLR) ligands for 24 hours before infection with VV. HaCat (d)
and normal human epidermal keratinocytes (NHEKs) (e, f) were infected with
VV after Poly(I:C) pretreatment for 24 hours. (c–e) Plaques were quantified
24 hours after infection. (f) Viral mRNA was quantified by quantitative real-
time PCR 8 hours after infection. (c–f) Statistical significance was determined
using one-way analysis of variance with Tukey post-tests; *Po0.05, **Po0.01,
***Po0.001, nd, not detectable. (g) VV was pretreated for 1 hour at 37 1C with
50mg ml1 BSA or recombinant human macrophage receptor with
collagenous structure (hMARCO) before adding to NHEK to assess viral plaque
formation. A two-tailed Student’s t-test was used to determine statistical
significance; ***Po0.001. (a–g) Error bars indicate SEM, n¼ 3. (h) A volume of
50ml of phosphate-buffered saline (PBS) or PBS containing 5 mg ml1 Poly(I) or
Poly(C) was applied to the depilated back skin of age-matched wild-type (WT)
female mice for 15 minutes prior to infection with VV. Wound sizes were
quantified at 6 days post-infection. Error bars indicate SEM, n¼ 4; statistical
significance was determined using one-way analysis of variance and a
Bonferroni post-test; *Po0.05. nd, not detectable.
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DISCUSSION
We demonstrate in this paper that VV binds directly to
MARCO, a scavenger receptor present on the surface of kerati-
nocytes. Importantly, overexpression of MARCO increased
susceptibility to VV infection, recombinant MARCO inhibited
infection of keratinocytes, and ligands capable of blocking this
interaction potently prevented infection of VV in keratinocytes
and mouse skin. These results identify MARCO as a receptor
that can be used by VV during infection in the skin. These
observations also show a potential new therapeutic approach
that may help limit VV infection in patients with AD who have
abundant expression of MARCO in their thickened lesional
epidermis.
A number of studies suggest that multiple receptors
have complementary roles to enable VV binding, thus
providing a complex and partially redundant system for the
virus to infect a variety of cell types. One such class of
molecules to which VV binds is cell surface heparan sulfate
proteoglycans. MARCO was recently shown by us to act in
conjunction with heparan sulfate proteoglycans to mediate
adsorption of HSV-1 to the cell surface (Macleod et al., 2013).
On the basis of our current results, we believe that a
similar mechanism is functioning for VV. Furthermore, in
addition to having multiple molecules to adhere to on the host
cell, the strain of virus and the type of cell being infected also
result in differences in the adsorption and entry of VV. Some
strains of VV exhibit less dependence on heparan sulfate
proteoglycans for adsorption compared with other strains
(Carter et al., 2005; Bengali et al., 2009). To dissect the
strain differences in viral binding, it is therefore important to
understand the molecules on the surface of the virus that are
mediating adsorption. The viral preparation used in our
experiments was primarily the intracellular mature virus
form of VV, which has at least seven proteins known or
predicted to be expressed or associated with the cell surface
(Duke-Cohan et al., 2009). The interaction with MARCO was
possibly mediated by the viral glycoproteins H3, A27, and D8,
all of which are present on the surface of intracellular mature
virus and have been shown to have roles in the adsorption of
VV by interactions with GAGs (Chung et al., 1998; Hsiao
et al., 1999; Lin et al., 2000). It is also possible that another
viral glycoprotein, such as A26, which binds to laminin (Chiu
et al., 2007), is also involved in the binding to MARCO. The
L1 protein is another interesting possibility, as this viral protein
has been shown to bind to cell surfaces and blocks infection
of VV in a GAG-independent manner by binding to an
unidentified cellular receptor (Foo et al., 2009). Further
experiments will be needed to identify the specific viral
glycoprotein capable of interacting with scavenger receptors
and to confirm whether the primary role of these receptors
is solely in adsorption of the virus to the cell surface or
whether they have an active role in uptake of the virus
as well. VV is taken up by target cells via macropinocytosis,
utilizing phosphatidylserine in the viral membrane to
mimic apoptotic debris and trigger uptake by a cellular
phosphatidylserine receptor (Mercer and Helenius, 2008;
Laliberte and Moss, 2009; Mercer et al., 2010). It is possible
that scavenger receptors are contributing to this process as
well; however, further experiments will be needed to test this
possibility.
Previously, it was expected that scavenger receptors serve
a protective role because of their capacity to facilitate the
detection of foreign pathogens. However, we have now
demonstrated that MARCO increases the susceptibility to
infection by binding to VV. This is consistent with a
previously described interaction between HSV-1 and
MARCO (Macleod et al., 2013) and the binding of the
closely related scavenger receptor macrophage scavenger
receptor 1 to Adenovirus 5 (Haisma et al., 2009). This
finding that an increasing number of diverse viruses exploit
class A scavenger receptors is very interesting. It is also
possible that these viruses use scavenger receptors as a way
to escape recognition by the innate immune system.
Indeed, it has been shown that although macrophage
scavenger receptor 1 and MARCO enhance uptake of
extracellular pathogen–associated molecular patterns for
recognition by intracellular pattern recognition receptors,
the presence of these receptors actually inhibits recognition
of extracellular pathogen–associated molecular patterns
by cell surface pattern recognition receptors, limiting the
subsequent activation of cell surface innate immune
defenses (Mukhopadhyay et al., 2011). In addition, although
class B scavenger receptors differ from the class A scavenger
receptors in terms of structure and function, a number of these
receptors have also been identified as receptors for viruses
including Hepatitis C virus (Scarselli et al., 2002), Coxsackie A
virus -7, -14, and -16 (Yamayoshi et al., 2012), and Enterovirus
71 (Yamayoshi et al., 2009).
The significant inhibition of VV by scavenger receptor
ligands in human cells and mouse skin is important, as this
shows that these ligands could potentially be used to block
scavenger receptors and limit VV infection in human skin.
Currently, treatment of severe cutaneous VV infection can
involve administration of vaccinia immune globulin (VIG);
however, VIG is currently classified by the Centers for Disease
Control and Prevention as an investigational drug, and
controlled studies determining the true efficacy of VIG and
other potentially useful antiviral drugs such as Cidofovir and
Riboviron are lacking (Bray, 2003). Although these treatments
appear to reduce the severity of infection, EV is still a life-
threatening infection that could benefit from additional thera-
peutics. Furthermore, it is likely that a combination of appro-
aches to target multiple aspects of the pathophysiology of VV
infection would be the most effective therapy. For example, it
has been shown that combined therapy of Poly(I:C) and VIG is
more effective to treat severe VV infection in mice compared
with either treatment alone (Worthington and Baron, 1973).
Thus, developing optimal treatments may require a combina-
tion of strategies to block viral binding, entry, and replication,
in addition to utilizing VIG to neutralize viral particles.
Blocking access to MARCO may thus be an important
component of future approaches to antiviral therapy. Further
studies will be needed to optimize treatment conditions and
fully evaluate the efficacy of scavenger receptor blockade as a
treatment for severe infections such as EV that arise as
complications from inoculation with VV.
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MATERIALS AND METHODS
Cells and viruses
Normal human epidermal keratinocytes were cultured in Epilife
media containing Epilife defined growth supplement (Life Technolo-
gies, Grand Island, NY), 0.06 mM calcium chloride, and 100 IU
Penicillin and 100mg Streptomycin per ml (VWR, Radnor, PA). BSC-1
cells (ATCC, Manassas, VA) and HaCat keratinocytes (a gift from
Rivkah Isseroff, University of California, Davis) were cultured in
DMEM (Lonza, Basel, Switzerland), 10% fetal bovine serum (Thermo
Fisher Scientific, Waltham, MA), 2 mM L-glutamine, and Penicillin/
Streptomycin (VWR). HaCat cells stably overexpressing MARCO and
control HaCat cells were generated as previously described (Macleod
et al., 2013). The Wyeth strain of VV (a kind gift from Michael Croft,
La Jolla Institute for Allergy and Immunology, CA), vB5R-GFP VV,
used for mouse experiments (a kind gift from Bernard Moss, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, MD), and HIV-1 JR-FL pseudovirus (a kind gift from Pascal
Poignard, International AIDS Vaccine Initiative, La Jolla, CA) were
prepared and titered from crude extracts of BSC-1 or 293T-infected
cells, lysed and centrifuged to remove cellular debris, and stored at
 80 1C.
Plaque assays
Cells were infected with VV for 1 hour, washed, and then incubated
in fresh media for 24 hours. Plaque formation was visualized by
staining cells with crystal violet. Multiplicity of infections were
typically selected to give approximately 100–500 plaques per well
in a six-well plate in each experiment. All plaque counts were
compared with the controls displayed for each individual experiment,
with plaque counts in the control wells normalized to 100%.
VV infection of murine skin
C57Bl/6 wild-type mice were purchased from the Jackson Laboratory,
Bar Harbor, ME. MARCO / mice were a gift from Andrij Holian
(Univerity of Montana, MT). All animal studies were in accordance
with the Public Health Service Policy on Humane Care and Use of
Laboratory Animals and were approved by UCSD IACUC (UCSD
Animal Welfare Assurance no. A3033-1). All procedures were
performed under isofluorane anesthesia, and all efforts were made
to minimize pain, discomfort, and suffering. Mice were depilated and
then infected 1 day later with 2 106 plaque-forming units vB5R-GFP
VV by skin scarification, 25 scratches with a 25-gauge needle within
a 1 cm2 area on the back. Mice were photographed once daily, and
lesion sizes were quantified with ImageJ (Rasband, W.S., U. S. National
Institutes of Health, Bethesda, MD). On day 6 post-infection, the mice
were killed, and skin from the wound site was biopsied and sent to
the Moores Cancer Center Histology and Immunohistochemistry Core
(La Jolla, CA) for fixation, sectioning, and staining with hematoxylin
and eosin.
ELISAs
Proteins were bound to EIA/RIA plates at 2.5mg ml 1 in sterile phos-
phate-buffered saline containing calcium and magnesium, pH 7.4
(Lonza, Basel, Switzerland), washed, blocked with phosphate-
buffered saline containing 3% BSA, and then incubated with VV or
HIV-1 pseudovirus diluted in DMEMþ 1% fetal bovine serum.
Unbound virus was removed by repeated wash steps with phosphate-
buffered saline. Bound virus was detected using a rabbit polyclonal
primary antibody recognizing VV (Abcam, Cambridge, MA) or a
biotinylated human antibody recognizing HIV-1 (a kind gift from
Pascal Poignard, International AIDS Vaccine Initiative, La Jolla, CA), a
horseradish peroxidase-conjugated secondary antibody or streptavi-
din, respectively (Santa Cruz Biotechnology, Santa Cruz, CA), and a
TMB substrate reagent (BD Biosciences Pharmigen, San Diego, CA)
and quantified using a microplate reader measuring absorbance at
450 nm and subtracting absorbance at 570 nm. Background binding
(binding of the same concentrations of VV or HIV-1 pseudovirus to
plates coated with BSA) was subtracted.
Quantitative real-time PCR
RNA and DNA were isolated using Trizol (Life Technologies, Grand
Island, NY), and RNA was reverse transcribed using iScript (Bio-Rad,
Hercules, CA). Predesigned Taqman primers/probes (Life Technolo-
gies) were used for the quantification of MARCO mRNA, and custom
Taqman Probes were used for VV DNA–dependent RNA polymerase
(RPO35) and glyceraldehyde-3-phosphate dehydrogenase mRNA and
DNA quantification using Taqman Gene Expression Master Mix (Life
Technologies) with a 7,300 Real-Time PCR System (Life Technolo-
gies) using the primer sequences listed below. Fold changes of target
genes were normalized to host cell glyceraldehyde-3-phosphate
dehydrogenase levels relative to the control treatments were calcu-
lated using the 2(DDCt) method, with untreated or vehicle-treated
samples normalized to 1 or 100% as indicated.
Quantitative reverse transcriptase in real-time primer/probe
sequences
Glyceraldehyde-3-phosphate dehydrogenase probe: 50-CATCCATGA
CAACTTTGGTA-30. VV RPO35 Probe: 50-ATTGAATTCTCTTCCCG
CGGATGCTG-30. Primers were purchased from Sigma-Aldrich,
St Louis, MO. Glyceraldehyde-3-phosphate dehydrogenase: 50-CCTA
GCACCCCTGGCCAAG-30, 50-TGGTCATGAGTCCTTCCACG-30; VV
RPO35: 50-GCCAATGAGGGTTCGAGTTC-30, 50-CAACATCCCGT
CGTTCATCA-30.
Reagents
Poly(I:C), Imiquimod, Peptidoglycan, and CpG DNA were purchased
from Invivogen, San Diego, CA. Malp-2 and Flagellin were purchased
from Enzo Life Sciences, Farmingdale, NY. BSA, lipopolysaccharide,
Poly(I), polycytidylic acid, dextran sulfate, and cyclophosphamide
were purchased from Sigma-Aldrich. Chloroquine phosphate was
purchased from Spectrum, Gardena, CA. Recombinant human and
mouse MARCO and human oxidized low-density lipoprotein (lectin-
like) receptor 1, IL-4, and IL-13 were purchased from R&D Systems,
Minneapolis, MN.
Stimulation with TLR ligands
HaCat keratinocytes were pretreated for 24 hours with 10mg ml 1
Poly(I:C), 5mg ml 1 Imiquimod, 5mg ml 1 CpG DNA, 100 ng ml 1
Malp-2, 1 ng ml 1 lipopolysaccharide, 100 ng ml 1 Flagellin, and
1mg ml 1 peptidoglycan before infection with VV and quantification
of viral plaque–forming units.
Skin immunofluorescence staining
All studies were approved by the Human Research Protection
program at the University of California, San Diego La Jolla, CA,
and were conducted in adherence to the Declaration of Helsinki
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Principles. Written informed consent was obtained from all donors for
all procedures. Skin biopsy samples were obtained from normal skin
and lesional/non-lesional skin of AD patients, frozen in Tissue-Tek
Optimal Cutting Temperature Compound (VWR), sectioned using a
cryotome, and stored on microscope slides at  80 1C until use. Cells
were fixed with cold acetone and stained for the presence of MARCO
using a mAb (a kind gift from Lester Kobzik, Harvard University,
Cambridge MA) and Keratin-14 polyclonal antibody (Santa Cruz
Biotechnology) and Alexa-fluor 488- and 568-labeled secondary
antibodies (Life Technologies), and counterstained with 4,6-diami-
dino-2-phenylindole. Images were captured using a BX41 microscope
(Olympus, Center Valley, PA).
Statistical analysis
Analyses were performed using GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego, CA; www.graphpad.com).
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